Trial Profile
A prospective, non-randomised, multicenter study on the efficacy and safety of ILUVIEN® in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT).
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Oct 2016
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms REACT
- 26 Oct 2016 New trial record